Jefferies Financial Group Inc. Decreases Stake in IQVIA Holdings Inc. $IQV

Jefferies Financial Group Inc. lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 41.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 133,815 shares of the medical research company’s stock after selling 92,873 shares during the period. Jefferies Financial Group Inc. owned approximately 0.08% of IQVIA worth $25,417,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of IQV. Physician Wealth Advisors Inc. grew its stake in shares of IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after purchasing an additional 134 shares during the period. Westside Investment Management Inc. lifted its stake in shares of IQVIA by 219.6% in the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 101 shares during the period. Atlantic Union Bankshares Corp purchased a new stake in IQVIA during the third quarter worth about $36,000. Asset Dedication LLC boosted its holdings in IQVIA by 224.0% during the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock worth $38,000 after buying an additional 168 shares in the last quarter. Finally, Rothschild Investment LLC grew its position in IQVIA by 85.5% during the second quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock worth $42,000 after buying an additional 124 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

IQV has been the subject of a number of research reports. Barclays upgraded shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target for the company in a research report on Friday. Truist Financial dropped their price objective on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research note on Thursday, February 19th. TD Cowen lifted their price objective on IQVIA from $215.00 to $245.00 and gave the stock a “hold” rating in a report on Thursday, January 22nd. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Finally, Stifel Nicolaus lowered their target price on IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and a consensus price target of $231.13.

IQVIA Trading Down 2.2%

Shares of IQV opened at $174.56 on Monday. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $247.04. The stock has a market cap of $29.62 billion, a price-to-earnings ratio of 22.21, a price-to-earnings-growth ratio of 1.68 and a beta of 1.39. The firm has a 50 day simple moving average of $207.22 and a 200-day simple moving average of $207.58.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. The firm had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.IQVIA’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Equities analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.